The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. As a trusted partner to health systems, PPTA drives broad and reliable access to plasma derived medicinal products with a focus on the well-being of patients and plasma donors. These therapies are used by small patient populations worldwide to treat a variety of rare diseases and serious medical conditions. PPTA works globally to: • Advocate for access to and affordability of therapies for patients • Engage in constructive dialogue with regulatory agencies • Collaborate with patient advocacy organizations PPTA also administers standards and programs that help ensure the quality and safety of plasma collection and manufacturing and protect both donors and patients. PLASMA AVAILABILITY • Responsibly Improve the Reliable Availability of Plasma • Advocate for global sufficiency of plasma • Pioneer plasma safety and manufacturing quality and support donor well-being • Drive progressive policies for plasma collections ACCESS TO THERAPIES • Advocate for Patient Access to Plasma Protein Therapies • Promote clinician authority and patient participation in treatment • decisions • Pursue reimbursement models recognizing the unique nature of plasma protein therapies • Shape decisions of authorities to improve plasma protein therapy availability • Forage partnerships that support patient-focused initiatives AWARENESS • Advance the Understanding of the Plasma Ecosystem • Encourage plasma donation globally • Generate and promote evidence-based information about plasma • Explain the importance, unique nature, and value of plasma protein therapies
